BioAffinity Technologies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$8.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
| FY 2026 Annual Earnings Release | 15 Mar 2027 |
Monitoring Framework
Key Performance Indicators
CyPath Lung Test Unit Sales Growth Quarterly146.0%Target: Greater than 100% growth for FY 2026
CyPath Lung Testing Revenue Quarterly361K
Number of Ordering Physician Offices and Clinics Quarterly2Target: Continued expansion in strategic markets
Watch Items
- Cash Burn and Liquidity RunwayTrigger: Cash balance falling below $2.0 millionAction: Evaluate further capital raising options, warrant inducement programs, or strategic partnerships to sustain operations.
- Regulatory Environment for Laboratory Developed Tests (LDTs)Trigger: FDA implementation of final rules restricting or heavily regulating LDTsAction: Assess compliance requirements, adjust commercialization strategy, and prepare for potential FDA trial submissions.
- Implementation of Reverse Stock SplitTrigger: Stock price consistently trading below Nasdaq's $1.00 minimum bid price requirementAction: Board to exercise its discretionary authority to implement the approved 1-for-2 to 1-for-250 reverse stock split to maintain listing.
Research as of 20 Jun 2026